The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
The ichthyoses are a group of lifelong genetic disorders which share characteristics of
generalized skin thickening, scaling and underlying cutaneous inflammation. There are no
therapies based on growing understanding of what causes the disease. However, there have been
recent discoveries of marked elevations in expression of interleukin-17A (IL-17A) and
IL-17-related cytokines in the skin of individuals with ichthyosis, which may explain the
inflammation. Investigators propose that IL-17-targeting therapeutics will safely suppress
the inflammation and possibly the other features of ichthyosis, improving quality of life.